Updates

August 14, 2019
Progenics Enters Collaboration with Veterans Affairs for Medical Image Analysis

Progenics Pharmaceuticals has entered a collaboration with Veteran Affairs Greater Los Angeles Healthcare System (VAGLAHS) to support the development of new machine learning tools ... Read more
August 12, 2019August 12, 2019
Breast, Ovarian Cancer Therapy Seen to Delay to Progression in Advanced Prostate Cancers in Phase 3 Trial

Men with metastatic castration-resistant prostate cancer (mCRPC) given Lynparza (olaparib), a breast and ovarian cancer treatment, went a clinically meaningful longer time without disease progression ... Read more
August 8, 2019
First Patients Dosed in Phase 2b Trial Testing Oral Docetaxel Treatment for Advanced Prostate Cancer

A Phase 2b clinical trial evaluating ModraDoc006/r, Modra Pharmaceutical’s investigational oral treatment for metastatic castration-resistant prostate cancer, has started dosing patients, the company announced. ModraDoc006/r ... Read more
August 7, 2019
Prostate Cancer Therapy Zytiga Makes WHO’s Essential Medicines List

Zytiga (abiraterone acetate), a kind of hormone therapy, has been added to the World Health Organization’s (WHO) Essential Medicines List for ... Read more
August 5, 2019
Xtandi Delays Disease Worsening in Metastatic Hormone-sensitive Prostate Cancer, Study Says

Adding Xtandi (enzalutamide) to androgen deprivation therapy (ADT) significantly delays disease progression or death in men with metastatic hormone-sensitive prostate cancer (mHSPC), regardless of how ... Read more

News

FDA Approves Nubeqa Tablets for Men with Non-metastatic Castration-resistant Prostate Cancer
August 1, 2019
The U.S. Food and Drug Administration (FDA) has approved Nubeqa (darolutamide) tablets to treat ...
News

Invitae Offers Free Genetic Testing, Counseling for Hereditary Prostate Cancer
July 31, 2019July 31, 2019
Invitae has launched a free genetic testing program to help connect prostate cancer patients ...
News

ADT Linked to Higher Alzheimer’s and Dementia Risk in Older Prostate Cancer Patients, Study Suggests
July 29, 2019July 29, 2019
Men with prostate cancer who undergo treatment with androgen deprivation therapy (ADT) — a ...
News

PyL Imaging Agent Ably Detects Lesions Outside the Prostate, Phase 2/3 Trial Shows
July 25, 2019
PyL, a new imaging agent for positron emission topography (PET) scans, can accurately detect ...
News

Video Series Tackles Prostate Cancer and ADT Use in Doctor-Patient Format
July 24, 2019
CURE Media Group has introduced a video discussion series on topics of concern to ...
News

MSN Labs to Launch Generic Version of Zytiga in U.S. Following FDA Approval
July 22, 2019
MSN Labs, the parent company of Novadoz Pharmaceuticals, is launching a generic version of ...

Subscribe to our mailing list

Get regular updates delivered to your email box.

Thanks! Please check your email for a confirmation email.

Liquid Biopsy Could Help Identify Aggressive Prostate Cancers, Study Says
July 18, 2019
A non-invasive test that examines microRNAs — small RNA molecules — in urine may ...
TRC253 Showing Effectiveness in Metastatic Castration-resistant Prostate Cancer Patients
July 17, 2019
The potential oral therapy TRC253 was well-tolerated and showed effectiveness in a subset of ...
Veyonda-LuPSMA Radiotherapy Safe, Well-tolerated in Advanced PC, Early Trial Results Show
July 15, 2019
Advantagene Reaches Enrollment Goal in Phase 2 Trial Testing Prostate Cancer Vaccine
July 11, 2019
Liquid Biopsy Assay Being Utilized in Zejula Trials for PC
July 10, 2019
68Ga-PSMA-11 Better than Axumin at Detecting PC Recurrence, Trial Shows
July 8, 2019

Adding Xtandi to Xofigo Does Not Raise Risk of Bone Issues in CRPC, Study Says
July 3, 2019
Metastatic castration-resistant prostate cancer (CRPC) patients who receive Xtandi (enzalutamide) plus Xofigo (radium-223) in ...
Phase 3 Trial of Topsalysin, Potential Treatment for Localized Prostate Cancer, Planned for Europe
July 1, 2019
Nanostics Launches Pivotal Study to Validate ClarityDX Prostate Diagnostic Test
June 27, 2019June 27, 2019
Report Identifies Proteins That Drive Spread in Castration-resistant PC
June 26, 2019

FDA OKs Phase 2 Trial of Ampligen Combo as Pre-surgery PC Treatment
June 24, 2019
The U.S. Food and Drug Administration (FDA) has authorized the initiation of a Phase ...
Investigational AMG 212 Shows Anti-cancer Activity in Advanced mCRPC in Phase 1 Trial
June 20, 2019
FDA Grants Arvinas’ ARV-110 Fast Track Designation for mCRPC
June 19, 2019

News

Most Prostate Cancer Patients on Active Surveillance Don’t Follow Monitoring Guidelines, Study Shows
June 17, 2019June 17, 2019
Most prostate cancer patients who choose to undergo active surveillance instead of treatment are ...
News

Study Shows How Prostate Cancer Cells Mimic Bone When They Metastasize
June 13, 2019June 13, 2019
Prostate cancer cells can activate genes associated with bone formation and mimic bone cells’ ...
News

Darolutamide/ADT Combo Delays Disease Worsening in Some PC, Phase 3 Trial Shows
June 12, 2019
Darolutamide in combination with androgen deprivation therapy (ADT) delays disease worsening in men with ...
News

Add-on Xtandi Prolongs Survival in Metastatic Hormone-sensitive PC, Trial Shows
June 6, 2019
Treatment with Xtandi (enzalutamide) and testosterone suppression prolonged the survival of men with metastatic ...
News

Trial Shows Erleada Can Prolong Metastatic Castration-sensitive PC Patients’ Lives
June 5, 2019
Adding Erleada (apalutamide), Janssen‘s next-generation androgen receptor inhibitor, to androgen deprivation therapy (ADT) can ...
News

American and Russian Scientists Team Up in Search for Potential Biomarker for Metastatic Prostate Cancer
June 3, 2019
Funded by a $380,000 grant from the National Cancer Institute, researchers at the University ...
News

Patient Survey Sheds Light on Emotional and Overall Impact of Prostate Cancer
May 30, 2019May 30, 2019
Men who are diagnosed with prostate cancer at later stages of the disease are ...
News

RB1 Mutations Linked to Worse Outcomes in Prostate Cancer Patients, Study Finds
May 29, 2019May 29, 2019
Men whose tumors contain mutations in the retinoblastoma (RB1) gene have higher risks of ...
News

Prostate Cancer Foundation Puts Patients on Path to Knowledge with Updated Guide, Resources
May 23, 2019May 23, 2019
The Prostate Cancer Foundation (PCF) has released its comprehensive Prostate Cancer Patient Guide with ...
News

Xtandi Extends Time to Disease Worsening in Certain Metastatic Prostate Cancer Patients – Without Added Side Effects – Study Shows
May 22, 2019May 22, 2019
Xtandi (enzalutamide), an androgen receptor inhibitor, significantly delays disease progression — as assessed through radiological ...
News

Xtandi Better, Cheaper than Zytiga for Treatment of mCRPC, Study Suggests
May 16, 2019
Treating chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC) patients with Xtandi (enzalutamide) leads to better ...
News

Evidence Supports Stereotactic Body Radiotherapy as a Standard of Care for Localized PC
May 13, 2019
Cumulative evidence to date supports the implementation of stereotactic body radiotherapy — a highly ...
News

Single Dose of Brachytherapy Safe, Effective for Localized PC, Study Shows
May 9, 2019
Men with low-risk prostate cancer can safely receive a single high dose of brachytherapy ...
News

Janssen Seeks Expanded FDA Approval of Erleada to Treat Metastatic Castration-sensitive Prostate Cancer
May 6, 2019
Janssen has submitted an application with the U.S. Food and Drug Administration (FDA) seeking ...
News

Essa Pharma’s Androgen Receptor Inhibitor, EPI-7386, Selected as Lead Candidate Therapy
May 2, 2019
EPI-7386, a new androgen receptor inhibitor, was selected as Essa Pharma‘s lead candidate therapy ...
News

Early Cancer Detection Test, Ccheck, May Reduce Number of Unnecessary Prostate Biopsies, Anixa Says
April 29, 2019
Ccheck, a new test for early cancer detection under development by Anixa Biosciences, was ...
News

Radiation, Hormone Therapy Extend Survival in Advanced PC, Phase 3 Trial Shows
April 24, 2019
A combination of androgen deprivation therapy (ADT) and external beam radiation therapy (EBRT) is ...
News

68Ga-PSMA-11 PET Scan Accurate, Safe in Detecting Recurrent PC, Study Says
April 22, 2019
68Ga-PSMA-11 PET scans are highly accurate, reproducible, and safe for detecting prostate cancer that ...

September 12, 2017September 12, 2017

Two High-Risk Prostate Cancer Treatments Have Similar Benefits, Add-On Study Finds

News

Two treatment approaches — Zytiga (abiraterone acetate) plus prednisolone (AAP) or Taxotere (docetaxel) — provided patients with high-risk prostate cancer similar benefits when added to standard hormone deprivation therapy, according to data recently presented at the European ... Read more

Pin It on Pinterest